NCT03303170View on ClinicalTrials.gov

Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris

NACompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

September 25, 2017

Primary Completion Date

April 10, 2018

Study Completion Date

April 10, 2018

Conditions
Acne Vulgaris
Interventions
DEVICE

Sebacia Microparticles

Topical microparticle suspension

DEVICE

Nd:Yag Laser

Laser delivering 1064 nm wavelength light

Trial Locations (11)

27612

Wake Research Associates, Raleigh

28207

Dermatology, Laser & Vein Institute, Charlotte

31406

Meridian Clinical Research, Savannah

33173

Miami Dermatology & Laser Institute, Miami

37130

International Clinical Research, Murfreesboro

64506

MediSearch Clinical Trials, Saint Joseph

77494

The Center for Skin Research, Katy

78660

Austin Institute for Clinical Research, Austin

85255

Clear Dermatology & Aesthetics Center, Scottsdale

92121

Scripps Health, San Diego

99202

Premier Clinical Research, Spokane

All Listed Sponsors
lead

Sebacia, Inc.

INDUSTRY

NCT03303170 - Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris | Biotech Hunter | Biotech Hunter